$EPAZ The Street Reports: Guide to Penny Stocks Lo
Post# of 40427
(Total Views: 100)
Posted On: 10/19/2023 9:25:25 AM
$EPAZ The Street Reports: Guide to Penny Stocks Look Now! CLNV, ARAV, RDHL, ATHX, EPAZ
Penny stocks attract considerable attention, but the more potent trick for investors to hunt for those stocks is by watching the trading activity. This feature would provide you with a closer look into penny stocks, which have been active over the past few days. Here is a look at four of those.
Clean Vision Corporation (OTC: CLNV): The company is one of the major innovators in the clean technology space, and on October 11, it announced that it had entered into a strategic agreement with Grant Thornton International. In its news release, Clean Vision Corporation noted that Grant Thornton was a leading worldwide advisory firm and would help it in issuing a maximum of $340 million in the form of green bonds.
The net proceeds from the issuance of the green bonds would be used by the company to form and operate the Plastic Conversion Network (PCN) under the Clean Seas umbrella across the world. The company further noted that the engagement with Grant Thornton was a major step towards the deployment of the PCN.
Another significant announcement from Clean Vision came about on September 7, when it revealed that the $1.75 million forgivable loan had been disbursed to it. The loan was pertaining to the Memorandum of Agreement that it had inked with the West Virginia Department of Economic Development. The company entered into the agreement on June 1, 2023. For the loan to be forgiven, the company would have to employ 40 people in a period of three years. The financing, which is non-dilutive in nature, would be used to fund the development of its Quincy, West Virginia-based plastic waste to circular waste facility.
Aravive Inc. (NASDAQ: ARAV) is a late-stage clinical company involved in the development of targeted therapeutics for treating metastatic disease. On October 17, the Aravive Inc. stock came into considerable focus and clocked gains of 62% amidst significant action.
On August 2, the company announced the Phase 3 AXLerate-OC trial for the purpose of evaluating the efficacy and safety of batiraxcept in platinum-resistant ovarian cancer. Aravive announced that the product failed to hit the primary endpoint of PFS (progression-free survival) in the subset of patients who had not been subjected to bevacizumab treatment previously. Additionally, it was noted at the time that the trial did not reveal any difference amongst the two different arms of the population, inclusive of patients who had been treated with bevacizumab in the past. At the time, Aravive announced that it would continue to evaluate the entirety of the dataset and come to a decision about the next steps.
RedHill Biopharma Ltd. (NASDAQ: RDHL) The specialty biopharmaceutical company made a key announcement about its product, opaganib, on October 3. RedHill Biopharma Ltd. announced that its unique twice-daily oral product recorded a statistically significant rise in survival time in an in vivo Ebola study conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).
The product was administered in two doses of 150 mg/kg daily. It was the first ever host-directed molecule that had managed to show activity in combating the Ebola virus disease. The study by the United States Army tested three doses of opaganib-50, 100, and 150 mg/kg BID-against an inactive vehicle control arm. The results showed a mean survival time of 11.2 days following 150 mg/kg doses as opposed to a mean survival time of 5.5 days in the inactive vehicle control group. Previously, the product had also shown antiviral benefits for patients suffering from moderate to severe symptoms of COVID-19 infection.
Athersys Inc. (NASDAQ: ATHX) The cell therapy and regenerative medicine firm is involved in the development of MultiStem for critical care. On October 16, Athersys Inc. announced that it had gone into a warrant exercise inducement offer letter by way of which it would raise gross proceeds to the tune of $3.9 million. It would do so through the exercise of 28124590 warrants. Additionally, the company also got the first tranche of a $1.5 million payment from Helios KK as per the provisions of the global license for acute respiratory syndrome.
The company announced that it entered into the warrant exercise inducement offer letter on October 11 with an existing warrant holder. The transaction was closed on October 16. It was also noted in the news release that Athersys engaged the services of Alliance Global Partners as its financial advisor for the transaction.
Epazz Inc. (OTC: EPAZ): The cloud-based software leader is a specialist in providing made-to-order cloud applications to corporations, public sector entities, and institutions of higher learning. Epazz Inc. also offers Epazz BoxesOS V3.0, which is described as a comprehensive web-based business software package for small to mid-sized businesses, governmental agencies, Fortune 500 companies, and higher education institutions.
On October 3, the company announced that its holding company, ZenaDrone, would send its first drones to Ireland. The drones had been at its new manufacturing plant. The shipment would comprise the first set of 20 ZenaDrone 1000s, which would help in the establishment of drone as a service (DaaS) operations in Ireland.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: editor@thestreetreports.com
Country: United States
Website: http://www.thestreetreports.com
Source: www.abnewswire.com
Penny stocks attract considerable attention, but the more potent trick for investors to hunt for those stocks is by watching the trading activity. This feature would provide you with a closer look into penny stocks, which have been active over the past few days. Here is a look at four of those.
Clean Vision Corporation (OTC: CLNV): The company is one of the major innovators in the clean technology space, and on October 11, it announced that it had entered into a strategic agreement with Grant Thornton International. In its news release, Clean Vision Corporation noted that Grant Thornton was a leading worldwide advisory firm and would help it in issuing a maximum of $340 million in the form of green bonds.
The net proceeds from the issuance of the green bonds would be used by the company to form and operate the Plastic Conversion Network (PCN) under the Clean Seas umbrella across the world. The company further noted that the engagement with Grant Thornton was a major step towards the deployment of the PCN.
Another significant announcement from Clean Vision came about on September 7, when it revealed that the $1.75 million forgivable loan had been disbursed to it. The loan was pertaining to the Memorandum of Agreement that it had inked with the West Virginia Department of Economic Development. The company entered into the agreement on June 1, 2023. For the loan to be forgiven, the company would have to employ 40 people in a period of three years. The financing, which is non-dilutive in nature, would be used to fund the development of its Quincy, West Virginia-based plastic waste to circular waste facility.
Aravive Inc. (NASDAQ: ARAV) is a late-stage clinical company involved in the development of targeted therapeutics for treating metastatic disease. On October 17, the Aravive Inc. stock came into considerable focus and clocked gains of 62% amidst significant action.
On August 2, the company announced the Phase 3 AXLerate-OC trial for the purpose of evaluating the efficacy and safety of batiraxcept in platinum-resistant ovarian cancer. Aravive announced that the product failed to hit the primary endpoint of PFS (progression-free survival) in the subset of patients who had not been subjected to bevacizumab treatment previously. Additionally, it was noted at the time that the trial did not reveal any difference amongst the two different arms of the population, inclusive of patients who had been treated with bevacizumab in the past. At the time, Aravive announced that it would continue to evaluate the entirety of the dataset and come to a decision about the next steps.
RedHill Biopharma Ltd. (NASDAQ: RDHL) The specialty biopharmaceutical company made a key announcement about its product, opaganib, on October 3. RedHill Biopharma Ltd. announced that its unique twice-daily oral product recorded a statistically significant rise in survival time in an in vivo Ebola study conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).
The product was administered in two doses of 150 mg/kg daily. It was the first ever host-directed molecule that had managed to show activity in combating the Ebola virus disease. The study by the United States Army tested three doses of opaganib-50, 100, and 150 mg/kg BID-against an inactive vehicle control arm. The results showed a mean survival time of 11.2 days following 150 mg/kg doses as opposed to a mean survival time of 5.5 days in the inactive vehicle control group. Previously, the product had also shown antiviral benefits for patients suffering from moderate to severe symptoms of COVID-19 infection.
Athersys Inc. (NASDAQ: ATHX) The cell therapy and regenerative medicine firm is involved in the development of MultiStem for critical care. On October 16, Athersys Inc. announced that it had gone into a warrant exercise inducement offer letter by way of which it would raise gross proceeds to the tune of $3.9 million. It would do so through the exercise of 28124590 warrants. Additionally, the company also got the first tranche of a $1.5 million payment from Helios KK as per the provisions of the global license for acute respiratory syndrome.
The company announced that it entered into the warrant exercise inducement offer letter on October 11 with an existing warrant holder. The transaction was closed on October 16. It was also noted in the news release that Athersys engaged the services of Alliance Global Partners as its financial advisor for the transaction.
Epazz Inc. (OTC: EPAZ): The cloud-based software leader is a specialist in providing made-to-order cloud applications to corporations, public sector entities, and institutions of higher learning. Epazz Inc. also offers Epazz BoxesOS V3.0, which is described as a comprehensive web-based business software package for small to mid-sized businesses, governmental agencies, Fortune 500 companies, and higher education institutions.
On October 3, the company announced that its holding company, ZenaDrone, would send its first drones to Ireland. The drones had been at its new manufacturing plant. The shipment would comprise the first set of 20 ZenaDrone 1000s, which would help in the establishment of drone as a service (DaaS) operations in Ireland.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: editor@thestreetreports.com
Country: United States
Website: http://www.thestreetreports.com
Source: www.abnewswire.com
(0)
(0)
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/